Press Releases

Dec 02, 2025 4:30pm EST

Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination

Dec 02, 2025 9:17am EST

Sonnet BioTherapeutics Holdings, Inc. Announces Stockholder Approval of Proposed Business Combination with Hyperliquid Strategies Inc

Nov 18, 2025 9:00am EST

Sonnet BioTherapeutics Holdings, Inc. Announces Adjournment of Special Meeting

Sep 19, 2025 9:00am EDT

Sonnet to Present at the MedInvest Biotech & Pharma Conference

Aug 11, 2025 9:15am EDT

Sonnet Releases Virtual Investor "What This Means" Segment

Aug 04, 2025 8:40am EDT

Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer

Jul 14, 2025 6:00am EDT

Sonnet BioTherapeutics, Inc. Announces $888 Million Business Combination to Launch a HYPE Cryptocurrency Treasury Reserve Strategy

May 01, 2025 9:00am EDT

Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit

Apr 16, 2025 9:10am EDT

Sonnet Releases Virtual Investor "What This Means" Segment

Apr 04, 2025 9:00am EDT

Sonnet’s SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose